Thu. 14 Mar 2024, 4:15pm ET
Benzinga
Earnings, News, Small Cap
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 42.86 percent decrease over losses of $(0.21) per share from the same period last year.